<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Infect Dis Ther</journal-id><journal-id journal-id-type="iso-abbrev">Infect Dis Ther</journal-id><journal-title-group><journal-title>Infectious Diseases and Therapy</journal-title></journal-title-group><issn pub-type="ppub">2193-8229</issn><issn pub-type="epub">2193-6382</issn><publisher><publisher-name>Springer Healthcare</publisher-name><publisher-loc>Cheshire</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27565805</article-id><article-id pub-id-type="pmc">5019983</article-id><article-id pub-id-type="publisher-id">127</article-id><article-id pub-id-type="doi">10.1007/s40121-016-0127-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Erratum</subject></subj-group></article-categories><title-group><article-title>Erratum to: Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Deck</surname><given-names>Daniel H.</given-names></name><address><email>Daniel.Deck@THEMEDCO.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Jordan</surname><given-names>Jennifer M.</given-names></name><address><email>Jennifer.jordan@themedco.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Holland</surname><given-names>Thomas L.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Fan</surname><given-names>Weihong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wikler</surname><given-names>Matthew A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sulham</surname><given-names>Katherine A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ralph Corey</surname><given-names>G.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>The Medicines Company, Parsippany, NJ USA </aff><aff id="Aff2"><label>2</label>Duke University Hospital, Durham, NC USA </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>8</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>8</month><year>2016</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2016</year></pub-date><volume>5</volume><issue>3</issue><fpage>363</fpage><lpage>365</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2016</copyright-statement></permissions><related-article related-article-type="corrected-article" id="d30e83" ext-link-type="doi" xlink:href="10.1007/s40121-016-0119-9"/><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Healthcare 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Erratum to: Infect Dis Ther (2016) DOI 10.1007/s40121-016-0119-9</title><p>Following publication of the aforementioned article, the authors noted a minor error in Table&#x000a0;1 and two small errors in Table&#x000a0;2. In Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, the Eron Class III Clinical Criteria should read CrCl &#x0003c;30&#x000a0;mL/min or on dialysis, not CrCl &#x0003c;20&#x000a0;mL/min. In Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>, Distribution of SOLO patients in modified Eron Classes I&#x02013;III, the number of outpatients receiving vancomycin (VAN) in Class I should be 111, not 11. The total number of inpatients (Class I&#x02013;III) was omitted, <italic>n</italic>&#x000a0;=&#x000a0;1143 (59.8%).<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Clinical criteria used to define modified Eron Classes I&#x02013;IV</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Eron class</th><th align="left">Clinical criteria</th></tr></thead><tbody><tr><td align="left">IV</td><td align="left">Bacteremia (positive blood culture); or<break/>Absolute total neutrophils count &#x0003c;500</td></tr><tr><td align="left">III</td><td align="left">Meeting SIRS criteria<break/>CrCl &#x0003c;30&#x000a0;mL/min or on dialysis<break/>ALT/AST &#x0003e;10-times ULN<break/>Heart rate &#x0003e;90/min, breath rate &#x0003e;20/min, or systolic BP &#x0003c;90&#x000a0;mmHg; or<break/>Cancer</td></tr><tr><td align="left">II</td><td align="left">Age &#x02265;75&#x000a0;years old<break/>Glucose &#x0003e;11.1&#x000a0;mmol/L<break/>Congestive heart failure at the randomization<break/>30&#x000a0;mL/min&#x000a0;&#x0003c;&#x000a0;CrCl &#x0003c;60&#x000a0;mL/min<break/>Hepatitis (excluding AST/ALT &#x0003e;10-times ULN)<break/>Peripheral vascular disease<break/>Diabetes mellitus<break/>Fever (temperature &#x0003e;38.0&#x000a0;&#x000b0;C); or<break/>BMI &#x02265;30&#x000a0;kg/m<sup>2</sup>
</td></tr><tr><td align="left">I</td><td align="left">For the patients who didn&#x02019;t meet Classes II&#x02013;IV</td></tr></tbody></table><table-wrap-foot><p>
<italic>ALT</italic> alanine transaminase, <italic>AST</italic> aspartate transaminase, <italic>BMI</italic> body mass index, <italic>BP</italic> blood pressure, <italic>CrCl</italic> creatinine clearance, <italic>SIRS</italic> systemic inflammatory response syndrome, <italic>ULN</italic> upper limit of normal</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Distribution of SOLO patients in modified Eron Classes I&#x02013;III (mITT population, <italic>n</italic>&#x000a0;=&#x000a0;1959)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Class I</th><th align="left">Class II</th><th align="left">Class III</th><th align="left">Total (Class I&#x02013;III)</th></tr></thead><tbody><tr><td align="left">SOLO mITT (<italic>n</italic>&#x000a0;=&#x000a0;1959)</td><td align="left">520 (26.5%)</td><td align="left">790 (40.3%)</td><td align="left">600 (30.6%)</td><td align="left">1910</td></tr><tr><td align="left">Inpatients, <italic>n</italic> (%)</td><td align="left">301 (57.9%)</td><td align="left">431 (54.6%)</td><td align="left">411 (68.5%)</td><td align="left">1143 (59.8%)</td></tr><tr><td align="left">ORI, <italic>n</italic>
</td><td align="left">144</td><td align="left">224</td><td align="left">203</td><td align="left">571</td></tr><tr><td align="left">VAN, <italic>n</italic>
</td><td align="left">157</td><td align="left">207</td><td align="left">208</td><td align="left">572</td></tr><tr><td align="left">Outpatients, <italic>n</italic> (%)</td><td align="left">219 (42.1%)</td><td align="left">359 (45.4%)</td><td align="left">189 (31.5%)</td><td align="left">767 (40.2%)</td></tr><tr><td align="left">ORI, <italic>n</italic>
</td><td align="left">108</td><td align="left">182</td><td align="left">89</td><td align="left">379</td></tr><tr><td align="left">VAN, <italic>n</italic>
</td><td align="left">111</td><td align="left">177</td><td align="left">100</td><td align="left">388</td></tr></tbody></table><table-wrap-foot><p>
<italic>mITT</italic> modified intent-to-treat, <italic>ORI</italic> oritavancin, <italic>VAN</italic> vancomycin</p></table-wrap-foot></table-wrap></p></sec></body><back><fn-group><fn><p>The online version of the original article can be found under doi:10.1007/s40121-016-0119-9.</p></fn></fn-group><ack><title>Open Access</title><p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</p></ack></back></article>